Overview
Study information
| Network: | MHRP |
| Grant Affiliation: | NA |
| Strategy: | Combo: Protein & vector vaccines |
| Study Type: | Phase III |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2003-09-01 |
| Study Made Public: | NA |
Title
A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP1521) Priming with VaxGen gp120 B/E (AIDSVAX B/E®) Boosting in HIV-uninfected Thai Adults
Description
RV144 (the Thai trial) is a Phase III, placebo-controlled, clinical trial to assess the efficacy of immunizations with an integrated combination of ALVAC-HIV (vCP1521) boosted by AIDSVAX gp120 B/E to prevent HIV infection.
Sign in to see full information about this study and to download study data.
Products
ALVAC (vCP1521) AIDSVAX B/E Saline (non-specific) Placebo ALVAC Placebo AIDSVAX B/EIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.